Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma.

Hegde GV, de la Cruz C, Giltnane JM, Crocker L, Venkatanarayan A, Schaefer G, Dunlap D, Hoeck JD, Piskol R, Gnad F, Modrusan Z, de Sauvage FJ, Siebel CW, Jackson EL.

Elife. 2019 May 30;8. pii: e46551. doi: 10.7554/eLife.46551.

2.

Antibody-mediated stabilization of NRG1 induces behavioral and electrophysiological alterations in adult mice.

Dominguez SL, Hegde GV, Hanson JE, Xiang H, Mandikian D, Boswell CA, Chiu C, Wu Y, Tsai SP, Fleck D, Weber M, Ngu H, Scearce-Levie K, Jackson EL.

Sci Rep. 2018 May 29;8(1):8239. doi: 10.1038/s41598-018-26492-4.

3.

An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.

Vinogradova M, Gehling VS, Gustafson A, Arora S, Tindell CA, Wilson C, Williamson KE, Guler GD, Gangurde P, Manieri W, Busby J, Flynn EM, Lan F, Kim HJ, Odate S, Cochran AG, Liu Y, Wongchenko M, Yang Y, Cheung TK, Maile TM, Lau T, Costa M, Hegde GV, Jackson E, Pitti R, Arnott D, Bailey C, Bellon S, Cummings RT, Albrecht BK, Harmange JC, Kiefer JR, Trojer P, Classon M.

Nat Chem Biol. 2016 Jul;12(7):531-8. doi: 10.1038/nchembio.2085. Epub 2016 May 23.

PMID:
27214401
4.

Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia.

Mittal AK, Chaturvedi NK, Rohlfsen RA, Gupta P, Joshi AD, Hegde GV, Bociek RG, Joshi SS.

PLoS One. 2013 Aug 1;8(8):e70352. doi: 10.1371/journal.pone.0070352. Print 2013.

5.

Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.

Hegde GV, de la Cruz CC, Chiu C, Alag N, Schaefer G, Crocker L, Ross S, Goldenberg D, Merchant M, Tien J, Shao L, Roth L, Tsai SP, Stawicki S, Jin Z, Wyatt SK, Carano RA, Zheng Y, Sweet-Cordero EA, Wu Y, Jackson EL.

Sci Transl Med. 2013 Feb 6;5(171):171ra18. doi: 10.1126/scitranslmed.3004438.

6.

Residual tumor cells that drive disease relapse after chemotherapy do not have enhanced tumor initiating capacity.

Hegde GV, de la Cruz C, Eastham-Anderson J, Zheng Y, Sweet-Cordero EA, Jackson EL.

PLoS One. 2012;7(10):e45647. doi: 10.1371/journal.pone.0045647. Epub 2012 Oct 24.

7.

Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling.

Hegde GV, Nordgren TM, Munger CM, Mittal AK, Bierman PJ, Weisenburger DD, Vose JM, Sharp JG, Joshi SS.

Int J Cancer. 2012 Dec 15;131(12):2951-60. doi: 10.1002/ijc.27602. Epub 2012 May 21.

8.

Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma.

Munger CM, Hegde GV, Weisenburger DD, Vose JM, Joshi SS.

Cancer Immunol Immunother. 2012 Oct;61(10):1819-32. Epub 2012 Mar 23.

PMID:
22441656
9.

Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target.

Hegde GV, Peterson KJ, Emanuel K, Mittal AK, Joshi AD, Dickinson JD, Kollessery GJ, Bociek RG, Bierman P, Vose JM, Weisenburger DD, Joshi SS.

Mol Cancer Res. 2008 Dec;6(12):1928-36. doi: 10.1158/1541-7786.MCR-08-0142.

10.

Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma.

Hegde GV, Munger CM, Emanuel K, Joshi AD, Greiner TC, Weisenburger DD, Vose JM, Joshi SS.

Mol Cancer Ther. 2008 Jun;7(6):1450-60. doi: 10.1158/1535-7163.MCT-07-2118. Epub 2008 Jun 4.

11.

A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cells.

Hegde GV, Meyers-Clark E, Joshi SS, Sanderson SD.

Int Immunopharmacol. 2008 Jun;8(6):819-27. doi: 10.1016/j.intimp.2008.01.031. Epub 2008 Mar 3.

PMID:
18442785
12.

Immunotherapy of human neuroblastoma using umbilical cord blood-derived effector cells.

Joshi AD, Clark EM, Wang P, Munger CM, Hegde GV, Sanderson S, Dave HP, Joshi SS.

J Neuroimmune Pharmacol. 2007 Jun;2(2):202-12. Epub 2006 Oct 10.

PMID:
18040845
13.

Erythropoietin induces excessive neointima formation: a study in a rat carotid artery model of vascular injury.

Reddy MK, Vasir JK, Hegde GV, Joshi SS, Labhasetwar V.

J Cardiovasc Pharmacol Ther. 2007 Sep;12(3):237-47.

PMID:
17875952
14.

ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia.

Joshi AD, Hegde GV, Dickinson JD, Mittal AK, Lynch JC, Eudy JD, Armitage JO, Bierman PJ, Bociek RG, Devetten MP, Vose JM, Joshi SS.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5295-304.

15.

Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.

Mittal AK, Hegde GV, Aoun P, Bociek RG, Dave BJ, Joshi AD, Sanger WG, Weisenburger DD, Joshi SS.

Int J Mol Med. 2007 Oct;20(4):461-9.

PMID:
17786276
16.
17.

Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion.

Joshi AD, Dickinson JD, Hegde GV, Sanger WG, Armitage JO, Bierman PJ, Bociek RG, Devetten MP, Vose JM, Joshi SS.

Cancer Genet Cytogenet. 2007 Jan 15;172(2):120-6.

PMID:
17213020
18.

Neural stem cell properties of Müller glia in the mammalian retina: regulation by Notch and Wnt signaling.

Das AV, Mallya KB, Zhao X, Ahmad F, Bhattacharya S, Thoreson WB, Hegde GV, Ahmad I.

Dev Biol. 2006 Nov 1;299(1):283-302. Epub 2006 Jul 29.

19.

Immunolocalization and functional role of Sclerotium rolfsii lectin in development of fungus by interaction with its endogenous receptor.

Swamy BM, Bhat AG, Hegde GV, Naik RS, Kulkarni S, Inamdar SR.

Glycobiology. 2004 Nov;14(11):951-7. Epub 2004 Jul 14.

PMID:
15253931
20.

Carbohydrate specificity of a lectin isolated from the fungus Sclerotium rolfsii.

Wu AM, Wu JH, Tsai MS, Hegde GV, Inamdar SR, Swamy BM, Herp A.

Life Sci. 2001 Sep 14;69(17):2039-50.

PMID:
11589519

Supplemental Content

Loading ...
Support Center